TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12/13/22 20:24 | 12/9/22 | TCRR | Tcr2 Therapeutics Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Olagunju Peter | MA | O | Chief Te | S.m | -5 | 1.10 | 0 | -5 | -8 | 53 | D | ||||||||||||||
12/9/22 16:42 | 12/7/22 | TCRR | Tcr2 Therapeutics Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Olagunju Peter | MA | O | Chief Te | S.m | -4 | 1.27 | 0 | -3 | -4 | 61 | D | ||||||||||||||
12/7/22 19:56 | 12/5/22 | TCRR | Tcr2 Therapeutics Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Olagunju Peter | MA | O | Chief Te | S.m | -4 | 1.35 | 0 | -3 | -4 | 66 | D | ||||||||||||||
12/5/22 19:50 | 12/1/22 | TCRR | Tcr2 Therapeutics Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Olagunju Peter | MA | O | Chief Te | M.d | 0 | 0.00 | 0 | 33 | 999% | 37 | D | ||||||||||||||
12/5/22 19:50 | 12/2/22 | TCRR | Tcr2 Therapeutics Inc. | DE | Health | BioPrd | Biological Products, (No Diag | Olagunju Peter | MA | O | Chief Te | S.d | -2 | 1.39 | 0 | -1 | -3 | 37 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |